title: Glucocorticoid-induced osteoporosis: when and who should we treat?
authors.forename: Gauthier
authors.initials: G
authors.lastname: Morel
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Biver
authors.forename: Séverine
authors.initials: S
authors.lastname: Borg
authors.forename: Florence
authors.initials: F
authors.lastname: Chopin
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Hoppé
authors.forename: Gérald
authors.initials: G
authors.lastname: Rajzbaum
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D015519:Bone Density; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D005260:Female; D005598:Fractures, Spontaneous / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids